Compare Gilead Sciences, Inc. (GILD) vs International Business Machines Corp (IBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs International Business Machines Corp — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while International Business Machines Corp trades at $226.61 (market cap $213.50B). The key difference: International Business Machines Corp is the larger of the two by market cap, and International Business Machines Corp pays the higher dividend (2.98%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and International Business Machines Corp for 88 Days on average.
| GILD | IBM | |
|---|---|---|
Market Cap | $182.40B | $213.50B |
Volume | 4,469,821 | 8,908,687 |
Sector | Health | Technology |
52-Week High | $155.80 | $329.23 |
52-Week Low | $116.74 | $205.77 |
Typical Hold Time | 111 Days | 88 Days |
Enterprise Value | $205.46B | $270.64B |
Dividend Yield | 2.23% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
IBM's stock trades at $220.51, down 0.35% on the day, amid a bearish technical signal. The company reported strong 2025 results with revenue of $67.54B and net income of $10.59B, beating earnings expectations in recent quarters. Analyst consensus is a Buy with a $256.69 price target, though technical indicators show resistance near $222. Recent news highlights IBM's focus on AI, including self-hosted deployment for its Bob platform.
IBM presents a mixed outlook with solid fundamentals and AI growth potential offset by near-term technical weakness and competitive pressures. The stock's valuation appears reasonable with a P/E of 19.58, but investors face risks from execution challenges and market volatility. Upside hinges on sustained earnings growth and successful AI integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
